Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $14.7 million.

  • Ligand Pharmaceuticals' Share-based Compensation fell 280.14% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.1 million, marking a year-over-year increase of 207.96%. This contributed to the annual value of $41.1 million for FY2024, which is 5961.23% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Share-based Compensation stood at $14.7 million for Q3 2025, which was down 280.14% from $10.0 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Share-based Compensation high stood at $29.1 million for Q4 2022, and its period low was $5.7 million during Q4 2023.
  • Its 5-year average for Share-based Compensation is $10.4 million, with a median of $9.5 million in 2022.
  • In the last 5 years, Ligand Pharmaceuticals' Share-based Compensation skyrocketed by 18002.5% in 2022 and then plummeted by 8037.06% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Share-based Compensation (Quarter) stood at $10.4 million in 2021, then surged by 180.02% to $29.1 million in 2022, then tumbled by 80.37% to $5.7 million in 2023, then surged by 31.52% to $7.5 million in 2024, then skyrocketed by 95.99% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $10.0 million for Q2 2025, and $7.8 million during Q1 2025.